Search Results - "Philippon, Jennifer"

Hypertension and incident cardiovascular events following ibrutinib initiation by Dickerson, Tyler, Wiczer, Tracy, Waller, Allyson, Philippon, Jennifer, Porter, Kyle, Haddad, Devin, Guha, Avirup, Rogers, Kerry A., Bhat, Seema, Byrd, John C., Woyach, Jennifer A., Awan, Farrukh, Addison, Daniel

“…Ibrutinib is associated with dramatic efficacy against B-cell malignancies. Yet, it has been linked with potentially limiting cardiotoxicity, including…”
Get full text

Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis by Quiroga, Dionisia, Liebner, David A, Philippon, Jennifer S, Hoffman, Sarah, Tan, Yubo, Chen, James L, Lenobel, Scott, Wakely, Jr, Paul E, Pollock, Raphael, Tinoco, Gabriel

“…Sarcomas constitute a heterogeneous group of tumors with different clinical behaviors and variable responses to systemic therapies. Recent immunotherapy…”
Get full text

Describing the role of the hematology/oncology clinical pharmacist in health information technology by Philippon, Jennifer S, Kusoski, Carolyn L, Kennerly-Shah, Julie M, Barreto, Janinah S

“…Purpose To describe the role of hematology/oncology clinical pharmacists in health information technology as well as their perceptions of the impact of…”
Get full text

Retrospective Indication-Matched Cohort Study of Reference Product and Biosimilar: Bevacizumab Versus Bevacizumab-Awwb by Booth, Jennifer Philippon, Pilz, Jeffrey

“…Introduction: Due to the abbreviated approval pathway and extrapolation to non-studied indications, an increased importance is placed on post-marketing…”
Get full text

882: HOME MEDICATIONS AS RISK FACTORS FOR ICU DELIRIUM DEVELOPMENT by Murphy, Claire, Zhang, Mengqi, Philippon, Jennifer, Scott, Elizabeth, Tate, Judith, Eiferman, Daniel

Get full text

Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies by Dickerson, Tyler, Wiczer, Tracy, Waller, Allyson, Philippon, Jennifer, Haddad, Devin, Guha, Avirup, Porter, Kyle, Rogers, Kerry A., Woyach, Jennifer A., Byrd, John C., Addison, Daniel, Awan, Farrukh T.

“…Background Ibrutinib (IB), a nonselective Bruton's tyrosine kinase inhibitor, is associated with significantly improved disease control rates, progression…”
Get full text

Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy by Spakowicz, Daniel, Husain, Marium, Tinoco, Gabriel, Patel, Sandip H., Burkart, Jarred Thomas, Verschraegen, Claire F., Kendra, Kari Lynn, Hoffman, Sarah, Philippon, Jennifer, Quiroga, Dionisia Marie, Otterson, Gregory Alan, Owen, Dwight Hall

“…Abstract only 94 Background: The response to Immunotherapy (IO) is known to be affected by concomitant medications including corticosteroids and antibiotics…”
Get full text